Dr. Oh on the Evolving Treatment Landscape in CLL

Stephen Oh, MD, PhD, associate professor, Department of Medicine, Division of Hematology, Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discuses the evolving treatment landscape of chronic lymphocytic leukemia (CLL).

The development of new agents has represented progress in the CLL treatment paradigm, Oh says. These agents have created the possibility for some patients to avoid traditional chemotherapy in the appropriate setting, Oh adds.

More experience has been gained regarding different targeted agents, particularly as they have shifted into the second and third generations, Oh explains. As more becomes known in terms of efficacy and safety profiles, it will help dictate treatment decisions, Oh concludes.